Literature DB >> 24972767

Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen.

Annalisa Ruggeri1, Myriam Labopin2, Maria Pia Sormani3, Guillermo Sanz4, Jaime Sanz4, Fernanda Volt5, Gerard Michel6, Franco Locatelli7, Cristina Diaz De Heredia8, Tracey O'Brien9, William Arcese10, Anna Paola Iori11, Sergi Querol12, Gesine Kogler13, Lucilla Lecchi14, Fabienne Pouthier15, Federico Garnier16, Cristina Navarrete17, Etienne Baudoux18, Juliana Fernandes5, Chantal Kenzey5, Mary Eapen19, Eliane Gluckman20, Vanderson Rocha21, Riccardo Saccardi22.   

Abstract

Umbilical cord blood transplant recipients are exposed to an increased risk of graft failure, a complication leading to a higher rate of transplant-related mortality. The decision and timing to offer a second transplant after graft failure is challenging. With the aim of addressing this issue, we analyzed engraftment kinetics and outcomes of 1268 patients (73% children) with acute leukemia (64% acute lymphoblastic leukemia, 36% acute myeloid leukemia) in remission who underwent single-unit umbilical cord blood transplantation after a myeloablative conditioning regimen. The median follow-up was 31 months. The overall survival rate at 3 years was 47%; the 100-day cumulative incidence of transplant-related mortality was 16%. Longer time to engraftment was associated with increased transplant-related mortality and shorter overall survival. The cumulative incidence of neutrophil engraftment at day 60 was 86%, while the median time to achieve engraftment was 24 days. Probability density analysis showed that the likelihood of engraftment after umbilical cord blood transplantation increased after day 10, peaked on day 21 and slowly decreased to 21% by day 31. Beyond day 31, the probability of engraftment dropped rapidly, and the residual probability of engrafting after day 42 was 5%. Graft failure was reported in 166 patients, and 66 of them received a second graft (allogeneic, n=45). Rescue actions, such as the search for another graft, should be considered starting after day 21. A diagnosis of graft failure can be established in patients who have not achieved neutrophil recovery by day 42. Moreover, subsequent transplants should not be postponed after day 42. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24972767      PMCID: PMC4562541          DOI: 10.3324/haematol.2014.109280

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  31 in total

1.  Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.

Authors:  Fusako Waki; Kazuhiro Masuoka; Takahiro Fukuda; Yoshinobu Kanda; Mika Nakamae; Kimikazu Yakushijin; Katsuhiro Togami; Kaichi Nishiwaki; Yasunori Ueda; Fumio Kawano; Masaharu Kasai; Koji Nagafuji; Maki Hagihara; Kazuo Hatanaka; Masafumi Taniwaki; Yoshinobu Maeda; Naoki Shirafuji; Takehiko Mori; Atae Utsunomiya; Tetsuya Eto; Hitoshi Nakagawa; Makoto Murata; Toshiki Uchida; Hiroatsu Iida; Kazuaki Yakushiji; Takuya Yamashita; Atsushi Wake; Satoshi Takahashi; Yoichi Takaue; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-16       Impact factor: 5.742

2.  The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.

Authors:  M Stelljes; A van Biezen; S Slavin; E Olavarria; R E Clark; A Nagler; V Koza; J Kienast; D Niederwieser; T de Witte; T Ruutu
Journal:  Bone Marrow Transplant       Date:  2008-08-25       Impact factor: 5.483

3.  Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

Authors:  Marcos de Lima; Ian McNiece; Simon N Robinson; Mark Munsell; Mary Eapen; Mary Horowitz; Amin Alousi; Rima Saliba; John D McMannis; Indreshpal Kaur; Partow Kebriaei; Simrit Parmar; Uday Popat; Chitra Hosing; Richard Champlin; Catherine Bollard; Jeffrey J Molldrem; Roy B Jones; Yago Nieto; Borje S Andersson; Nina Shah; Betul Oran; Laurence J N Cooper; Laura Worth; Muzaffar H Qazilbash; Martin Korbling; Gabriela Rondon; Stefan Ciurea; Doyle Bosque; Ila Maewal; Paul J Simmons; Elizabeth J Shpall
Journal:  N Engl J Med       Date:  2012-12-13       Impact factor: 91.245

4.  Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation.

Authors:  Juliana Fernandes; Vanderson Rocha; Marie Robin; Régis Peffault de Latour; Richard Traineau; Agnès Devergie; Patricia Ribaud; Delphine Réa; Jérôme Larghero; Eliane Gluckman; Gérard Socié
Journal:  Br J Haematol       Date:  2007-05       Impact factor: 6.998

5.  Second unrelated donor hematopoietic cell transplantation for primary graft failure.

Authors:  Jeffrey Schriber; Manza-A Agovi; Vincent Ho; Karen K Ballen; Andrea Bacigalupo; Hillard M Lazarus; Christopher N Bredeson; Vikas Gupta; Richard T Maziarz; Gregory A Hale; Mark R Litzow; Brent Logan; Martin Bornhauser; Roger H Giller; Luis Isola; David I Marks; J Douglas Rizzo; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-19       Impact factor: 5.742

6.  Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.

Authors:  Mary J Laughlin; Mary Eapen; Pablo Rubinstein; John E Wagner; Mei-Jei Zhang; Richard E Champlin; Cladd Stevens; Juliet N Barker; Robert P Gale; Hillard M Lazarus; David I Marks; Jon J van Rood; Andromachi Scaradavou; Mary M Horowitz
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

7.  Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF.

Authors:  D J Weisdorf; C M Verfaillie; S M Davies; A H Filipovich; J E Wagner; J S Miller; J Burroughs; N K Ramsay; J H Kersey; P B McGlave
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

8.  Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis.

Authors:  Annalisa Ruggeri; Vanderson Rocha; Emeline Masson; Myriam Labopin; Renato Cunha; Lena Absi; Ali Boudifa; Brigitte Coeffic; Anne Devys; Muriel De Matteis; Valérie Dubois; Daniel Hanau; Françoise Hau; Isabelle Jollet; Dominique Masson; Beatrice Pedron; Pascale Perrier; Christophe Picard; Annie Ramouneau-Pigot; Fernanda Volt; Dominique Charron; Eliane Gluckman; Pascale Loiseau
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

9.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Philip B McGlave; Jeffrey S Miller; Catherine M Verfaillie; John E Wagner
Journal:  Blood       Date:  2004-10-05       Impact factor: 22.113

10.  Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies.

Authors:  Federico Moscardó; Jaime Sanz; Leonor Senent; Susana Cantero; Javier de la Rubia; Pau Montesinos; Dolores Planelles; Ignacio Lorenzo; Jose Cervera; Javier Palau; Miguel A Sanz; Guillermo F Sanz
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

View more
  14 in total

Review 1.  Improving Quality and Potency Testing for Umbilical Cord Blood: A New Perspective.

Authors:  Ivan N Rich
Journal:  Stem Cells Transl Med       Date:  2015-07-09       Impact factor: 6.940

2.  Impact of Graft-Recipient ABO Compatibility on Outcomes after Umbilical Cord Blood Transplant for Nonmalignant Disease.

Authors:  Matthew R Kudek; Ryan Shanley; Nicole D Zantek; David H McKenna; Angela R Smith; Weston P Miller
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-02       Impact factor: 5.742

3.  A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database.

Authors:  N Kurita; M Gosho; Y Yokoyama; T Kato; N Obara; M Sakata-Yanagimoto; Y Hasegawa; N Uchida; S Takahashi; Y Kouzai; Y Atsuta; M Kurata; T Ichinohe; S Chiba
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

4.  Real Time Immunophenotyping of Leukocyte Subsets Early after Double Cord Blood Transplantation Predicts Graft Function.

Authors:  Jianqiang Li; Ian Nicoud; Joseph Blake; David Oliver; Emily Cox; Shelly Heimfeld; Filippo Milano; Suzan Imren; Colleen Delaney
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-19       Impact factor: 5.742

5.  Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation.

Authors:  N Kawashima; S Terakura; S Nishiwaki; D Koyama; Y Ozawa; M Ito; K Miyamura
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

6.  Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI.

Authors:  T Cluzeau; J Lambert; N Raus; K Dessaux; L Absi; F Delbos; A Devys; M De Matteis; V Dubois; M Filloux; M Fort; F Hau; I Jollet; M Labalette; D Masson; B Mercier; B Pedron; P Perrier; C Picard; F Quainon; A Ramounau-Pigot; V Renac; P Van Endert; D Charron; R Peffault de la Tour; J L Taupin; P Loiseau
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

7.  Hematopoietic stem cell transplantation for infantile osteopetrosis.

Authors:  Paul J Orchard; Anders L Fasth; Jennifer Le Rademacher; Wensheng He; Jaap Jan Boelens; Edwin M Horwitz; Amal Al-Seraihy; Mouhab Ayas; Carmem M Bonfim; Farid Boulad; Troy Lund; David K Buchbinder; Neena Kapoor; Tracey A O'Brien; Miguel A Diaz Perez; Paul A Veys; Mary Eapen
Journal:  Blood       Date:  2015-05-26       Impact factor: 22.113

8.  Detecting primitive hematopoietic stem cells in total nucleated and mononuclear cell fractions from umbilical cord blood segments and units.

Authors:  John Patterson; Cally H Moore; Emily Palser; Jason C Hearn; Daniela Dumitru; Holli A Harper; Ivan N Rich
Journal:  J Transl Med       Date:  2015-03-18       Impact factor: 5.531

Review 9.  Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.

Authors:  Juan Montoro; José Luis Piñana; Federico Moscardó; Jaime Sanz
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-18       Impact factor: 2.576

10.  Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.

Authors:  C Ustun; F Giannotti; M-J Zhang; H-L Wang; C Brunstein; M Labopin; V Rocha; M de Lima; F Baron; B M Sandmaier; M Eapen; E Gluckman; A Nagler; D J Weisdorf; A Ruggeri
Journal:  Leukemia       Date:  2017-01-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.